On this page
Cryopyrin-associated periodic syndromes
These syndromes result from overactive immune signalling, causing unprovoked inflammatory episodes that can affect the skin, joints, eyes, and nervous system. Severity ranges from mild recurring rashes to serious multi-system involvement requiring specialist management.
Overview
Cryopyrin-associated periodic syndromes (CAPS) encompass a spectrum of autoinflammatory disorders that share a common genetic cause. The three main presentations within this spectrum are familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and neonatal-onset multisystem inflammatory disease (NOMID), sometimes called chronic infantile neurological cutaneous and articular syndrome (CINCA). These conditions differ in severity but represent variations of the same underlying problem: excessive production of inflammatory signals by the immune system without an external trigger such as infection.
The syndromes are rare, though exact prevalence figures across the UK population are not well established. FCAS typically presents as the mildest form, whilst NOMID represents the most severe end of the spectrum. Recognition of these conditions has improved substantially in recent decades, particularly since targeted treatments became available that can effectively control inflammation in many affected individuals.
Symptoms & clinical features
Clinical features vary depending on where an individual falls within the CAPS spectrum. Many people experience recurring episodes of fever, often accompanied by a distinctive urticaria-like rash that differs from typical allergic hives because it does not respond to antihistamines. Joint pain and swelling commonly occur, particularly affecting the knees and ankles. Conjunctivitis or other eye inflammation may develop during flares.
In more severe presentations, particularly NOMID, symptoms often begin in infancy and may include persistent daily symptoms rather than distinct episodes. Headaches can signal chronic meningitis, whilst hearing loss may progressively worsen if inflammation affects the inner ear structures. Bone overgrowth, particularly around the knees, sometimes develops in severely affected individuals. Cold exposure often triggers or worsens symptoms in FCAS, though this pattern is less consistent in other CAPS variants.
Video: Genetics 101
Affected organs
The inflammatory process in CAPS can affect multiple organ systems. Skin involvement is nearly universal, with the characteristic rash typically appearing on the trunk and limbs. Joints frequently experience inflammation, though this usually does not cause permanent damage in milder forms. The eyes may develop uveitis or conjunctivitis, requiring monitoring to prevent vision complications.
The nervous system can be significantly affected, particularly in NOMID. Chronic aseptic meningitis causes ongoing inflammation around the brain and spinal cord, potentially leading to raised intracranial pressure and headaches. The inner ear structures may sustain progressive damage, resulting in sensorineural hearing loss. Bones and cartilage can develop abnormal overgrowth patterns in severe cases, whilst kidney inflammation (amyloidosis) represents a serious potential complication if systemic inflammation remains poorly controlled over many years.
Risks & severity
Severity varies considerably across the CAPS spectrum. Individuals with FCAS typically experience relatively mild episodes triggered by cold exposure, with symptoms resolving between flares and generally good long-term outcomes. Muckle-Wells syndrome presents with more frequent episodes and carries risk of progressive hearing loss and amyloidosis if inflammation is not adequately controlled.
NOMID represents the most severe presentation, often beginning in the newborn period with continuous rather than episodic symptoms. Without treatment, affected individuals face substantial risk of progressive neurological damage, vision loss, and hearing impairment. Growth delay may occur in childhood. The development of targeted anti-inflammatory treatments has dramatically improved outcomes, though early diagnosis and treatment initiation remain crucial for preventing irreversible damage to the nervous system and sensory organs.
Genetic causes
CAPS results from pathogenic variants in NLRP3, which encodes a protein called cryopyrin that plays a central role in immune system regulation. Cryopyrin normally functions as part of the inflammasome, a molecular complex that activates inflammatory responses when the immune system detects danger signals. The protein helps determine when to release interleukin-1 beta, a powerful inflammatory messenger molecule that coordinates fever and other inflammatory responses.
Pathogenic changes in NLRP3 cause the cryopyrin protein to become overactive, triggering excessive inflammasome activation even without appropriate danger signals. This leads to uncontrolled release of interleukin-1 beta, producing the characteristic inflammatory symptoms of CAPS. The severity of different CAPS presentations often correlates with how dramatically the variant affects protein function, though considerable variation exists even among individuals carrying identical variants.
- NLRP3 NLR family pyrin domain containing 3
Inheritance pattern
Cryopyrin-associated periodic syndromes follow an autosomal dominant inheritance pattern, meaning a pathogenic variant in just one copy of NLRP3 is sufficient to cause the condition. An affected parent has a 50% chance of passing the variant to each child, regardless of the child's sex.
However, many individuals with CAPS have no family history because their variant arose as a new (de novo) change during early development. This particularly applies to more severe presentations like NOMID, where the condition may significantly impact reproductive fitness. When a variant occurs de novo, the recurrence risk for future siblings is very low, though parents may wish to discuss the small possibility of germline mosaicism with a genetic counsellor.
Each child of an affected parent has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
Diagnosis of CAPS typically begins with clinical recognition of the characteristic pattern of recurrent or persistent inflammation, particularly when accompanied by the distinctive rash, fever, and multi-system features. Blood tests during symptomatic episodes usually show elevated inflammatory markers, though these are non-specific findings.
Genetic testing of NLRP3 confirms the diagnosis in most cases. This testing is available through the NHS Genomic Medicine Service for individuals meeting clinical criteria. Clinical genetics services assess referrals and arrange appropriate testing, which typically involves sequencing the NLRP3 gene to identify pathogenic variants. Occasionally, individuals with strong clinical features of CAPS do not have identifiable NLRP3 variants on standard testing, possibly reflecting variants in regulatory regions not covered by routine analysis or involvement of other genes. Genetic counsellors can discuss testing implications for the individual and family members.
Management & lifestyle
Management of CAPS has been transformed by targeted biological therapies that block interleukin-1 signalling. Medications such as anakinra, canakinumab, and rilonacept can dramatically reduce inflammation in most affected individuals, controlling symptoms and preventing progressive organ damage. Specialist immunology or rheumatology teams oversee treatment decisions and monitoring.
Regular monitoring is essential to detect and manage potential complications. This includes hearing assessments to identify progressive hearing loss early, ophthalmology reviews to check for eye inflammation, and neurological monitoring in individuals with CNS involvement. Some people require additional medications to manage specific symptoms such as pain. Genetic counselling helps families understand inheritance patterns and reproductive options. Living with CAPS may require practical adjustments, particularly for individuals with FCAS who need strategies to minimise cold exposure, though effective anti-inflammatory treatment often substantially improves quality of life.
UK care pathway
Within the NHS Genomic Medicine Service, CAPS falls under autoinflammatory disorder testing pathways. Clinical genetics services accept referrals from general practitioners, paediatricians, immunologists, or rheumatologists when an individual's clinical presentation suggests CAPS. The R67 code covers periodic fever syndromes within NHS genomic testing directories.
Following genetic confirmation, ongoing care typically involves specialist immunology or rheumatology services with experience managing autoinflammatory conditions. Multidisciplinary input may include audiology, ophthalmology, and neurology depending on which organ systems are affected. Genetic counsellors remain available to discuss inheritance, family planning, and testing of relatives who may carry the familial variant but have minimal symptoms.
Frequently asked questions
Will my children definitely inherit this condition if I have CAPS?
Each of your children has a 50% chance of inheriting the NLRP3 variant. However, inheriting the variant does not guarantee identical symptoms to yours, as severity can vary considerably even within families carrying the same genetic change.
Can CAPS be cured?
CAPS cannot currently be cured because the underlying genetic variant remains present throughout life. However, targeted treatments blocking interleukin-1 can effectively control inflammation in most people, often allowing normal or near-normal daily activities and preventing progressive complications.
Why do some people with CAPS have much worse symptoms than others?
Severity partly relates to which specific variant someone carries and how dramatically it affects protein function. However, even identical variants can produce different severity between individuals, suggesting other genetic or environmental factors influence how the condition manifests.
Should my relatives be tested even if they have no symptoms?
This depends on individual circumstances and family preferences. Some people with NLRP3 variants have very mild symptoms they may not recognise as related to CAPS. Genetic counsellors can discuss the potential benefits and limitations of testing asymptomatic relatives, including implications for their future health monitoring and family planning.
References
- Gattorno M, Hofer M, Federici S. Classification criteria for autoinflammatory recurrent fevers. Annals of the rheumatic diseases. 2019. PMID: 31018962
- Rilonacept. 2012. PMID: 31643801
- Romano M, Arici ZS, Piskin D. The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. Annals of the rheumatic diseases. 2022. PMID: 35623638
- Spel L, Hou C, Theodoropoulou K. HSP90β controls NLRP3 autoactivation. Science advances. 2024. PMID: 38416826
- Yacoub MR, Ferlito A, Nettis E. Chronic urticaria and autoinflammatory syndromes. Current opinion in allergy and clinical immunology. 2025. PMID: 40747632
- Gusdorf L, Lipsker D. Neutrophilic urticarial dermatosis: A review. Annales de dermatologie et de venereologie. 2018. PMID: 30224079
- Booshehri LM, Hoffman HM. CAPS and NLRP3. Journal of clinical immunology. 2019. PMID: 31077002
- Orakwue A, Bray J, Comfere N. Neutrophilic Urticarial Dermatosis. Dermatologic clinics. 2024. PMID: 38423683